Advertisement

Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue

Wojciech Jankowski, Joseph McGill, H. A. Daniel Lagassé, Stepan Surov, Gary Bembridge, Campbell Bunce, Edward Cloake, Mark H. Fogg, Katarzyna I. Jankowska, Abdul Khan, Joseph Marcotrigiano, Mikhail V. Ovanesov and Zuben E. Sauna

Article Information

Citation 
vol. 3 no. 17 2668-2678
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted April 22, 2019
  • Accepted July 3, 2019
  • Published online September 10, 2019.


Contributors 
  • Wojciech Jankowski, 1Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD;
  • Joseph McGill, 1Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD;
  • H. A. Daniel Lagassé, 1Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD;
  • Stepan Surov, 1Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD;2Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia;
  • Gary Bembridge, 3Abzena, Babraham Research Campus, Cambridge, United Kingdom;
  • Campbell Bunce, 3Abzena, Babraham Research Campus, Cambridge, United Kingdom;
  • Edward Cloake, 3Abzena, Babraham Research Campus, Cambridge, United Kingdom;
  • Mark H. Fogg, 3Abzena, Babraham Research Campus, Cambridge, United Kingdom;
  • Katarzyna I. Jankowska, 4Laboratory of Cellular Hematology, Division of Blood Components and Devices, Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD; and
  • Abdul Khan, 5Department of Chemistry and Chemical Biology, Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ
  • Joseph Marcotrigiano, 5Department of Chemistry and Chemical Biology, Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ
  • Mikhail V. Ovanesov, 1Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD;
  • Zuben E. Sauna, 1Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output